<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535662</url>
  </required_header>
  <id_info>
    <org_study_id>ORV-1-01</org_study_id>
    <nct_id>NCT03535662</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Male Participants to Determine the Effect of an Inhibitor of Cytochrome P450 3A and P Glycoprotein on Exposure to Orvepitant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerre Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerre Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 study to assess the effect of itraconazole, a strong inhibitor of CYP3A and
      P-glycoprotein, on the pharmacokinetics (PK) of orvepitant in healthy male volunteers.

      Subjects will receive two single doses of 20mg orvepitant, once alone and once in combination
      with repeat doses of itraconazole. All subjects will follow the same sequence - orvepitant
      alone followed by orvepitant in combination with itraconazole.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to orvepitant</measure>
    <time_frame>0 to 168 hours post dose</time_frame>
    <description>Area Under Curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pharmacokinetic Study in Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Orvepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orvepitant single 20mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orvepitant and itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orvepitant single 20mg dose in combination with repeat dose itraconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orvepitant</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Orvepitant</arm_group_label>
    <arm_group_label>Orvepitant and itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Once daily dosing for 10 days</description>
    <arm_group_label>Orvepitant and itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  male volunteers

          -  judged to be in good health, based on the results of medical history, physical
             examination, vital signs, 12 lead ECG, and clinical laboratory findings

          -  body weight greater than 50 kg and body mass index (BMI) within the range 18 to 30
             kg/m2 (inclusive)

        Key Exclusion Criteria:

          -  clinically significant findings on physical examination

          -  relevant medical history

          -  history of or considered at high risk of seizures (except febrile fits in childhood),
             including history of significant head injury

          -  positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody
             (anti-HCV) or human immunodeficiency virus (HIV)

          -  serum biochemistry and full blood count considered by the Investigator to be of
             clinical significance

          -  systolic blood pressure &lt;100 or &gt;140 mmHg or diastolic BP &lt;50 or Ëƒ90 mmHg, measured
             prior to the first dose of orvepitant

          -  abnormal 12 lead electrocardiogram (ECG)

          -  has donated one or more units (approximately 450 mL) of blood or acute loss of an
             equivalent amount of blood within 90 days prior to study intervention administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL EPCU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Ballantyne</last_name>
    <phone>44 (0) 1438 906960</phone>
    <email>elizabeth.ballantyne@nerretherapeutics.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

